HK$ 7.07
Key Takeaways
Risk factor
Good trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections;...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA, ov
Target Price
The average target price of 1177.HK is 9.1 and suggests 28% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
